Cite
Correction: Identification and validation of TNFRSF4 as a high-profile biomarker for prognosis and immunomodulation in endometrial carcinoma
MLA
Heng Ma, et al. “Correction: Identification and Validation of TNFRSF4 as a High-Profile Biomarker for Prognosis and Immunomodulation in Endometrial Carcinoma.” BMC Cancer, vol. 22, no. 1, May 2022, p. 1. EBSCOhost, https://doi.org/10.1186/s12885-022-09692-0.
APA
Heng Ma, Peng-Hui Feng, Shuang-ni Yu, Zhao-Hui Lu, Qi Yu, & Jie Chen. (2022). Correction: Identification and validation of TNFRSF4 as a high-profile biomarker for prognosis and immunomodulation in endometrial carcinoma. BMC Cancer, 22(1), 1. https://doi.org/10.1186/s12885-022-09692-0
Chicago
Heng Ma, Peng-Hui Feng, Shuang-ni Yu, Zhao-Hui Lu, Qi Yu, and Jie Chen. 2022. “Correction: Identification and Validation of TNFRSF4 as a High-Profile Biomarker for Prognosis and Immunomodulation in Endometrial Carcinoma.” BMC Cancer 22 (1): 1. doi:10.1186/s12885-022-09692-0.